At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 443 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Long-Term Safety Study of Tirzepatide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus (SURPASS J-combo)
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Oral antihyperglycemic medication (OAM) for Type 2 Diabetes Mellitus. Completed, enrolled 443 participants across 34 sites.
Detailed Summary
The purpose of this study is to determine the long-term safety of the study drug tirzepatide in combination with oral antihyperglycemic medications in participants with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMar 2019
Enrollment StartMar 2019
Primary CompletionJan 2021
Study CompletionFeb 2021
TodayJul 2026
First PostedMar 4, 2019
Enrollment StartMar 30, 2019
Primary CompletionJan 26, 2021
Study CompletionFeb 16, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.3 years ago
Interventions
Tirzepatidedrug
Administered SC
Oral antihyperglycemic medication (OAM)drug
Oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.